Potential Therapeutic Applications of Pulmonary Surfactant Lipids in the Host Defence Against Respiratory Viral Infections [PDF]
Frontiers in Immunology, 2021 Pulmonary surfactant is a complex and highly surface-active material. It covers the alveolar epithelium and consists of 90% lipids and 10% proteins. Pulmonary surfactant lipids together with pulmonary surfactant proteins facilitate breathing by reducing ...
Jianjian Ji +7 more
doaj +3 more sources
PLoS ONE, 2020 Smoke exposure is known to decrease total pulmonary surfactant and alter its composition, but the role of surfactant in chronic obstructive pulmonary disease (COPD) remains unknown. We aimed to analyze the compositional changes in the surfactant lipidome
Christina W Agudelo +8 more
doaj +3 more sources
Pulmonary surfactant and prostaglandin E2 in airway smooth muscle relaxation of human and male guinea pigs [PDF]
Physiological ReportsPulmonary surfactant serves as a barrier to respiratory epithelium but can also regulate airway smooth muscle (ASM) tone. Surfactant (SF) relaxes contracted ASM, similar to β2‐agonists, anticholinergics, nitric oxide, and prostanoids. The exact mechanism
J. Hanusrichterova +14 more
doaj +3 more sources
European Respiratory Review, 2021 Pulmonary surfactant is a crucial and dynamic lung structure whose primary functions are to reduce alveolar surface tension and facilitate breathing.
Nadia Milad, Mathieu C. Morissette
doaj +2 more sources
Biophysicochemical interaction of a clinical pulmonary surfactant with nano-alumina [PDF]
Langmuir, 2015 We report on the interaction of pulmonary surfactant composed of phospholipids and proteins with nanometric alumina (Al2O3) in the context of lung exposure and nanotoxicity.
Berret, J. -F. +3 more
core +4 more sources
The influence of natural pulmonary surfactant on the efficacy of siRNA-loaded dextran nanogels [PDF]
Nanomedicine, 2013 Aim: Topical administration of siRNA nanocarriers is a promising approach in the treatment of pulmonary disorders. Pulmonary surfactant, covering the entire alveolar surface of mammalian lungs, will be one of the first interfaces that siRNA nanocarriers ...
Braeckmans, Kevin +4 more
core +2 more sources
Effect of Amphotericin B on the Thermodynamic Properties and Surface Morphology of the Pulmonary Surfactant Model Monolayer during Respiration [PDF]
Molecules, 2023 During the COVID-19 pandemic, the treatment of pulmonary fungal infection faced noteworthy challenges. Amphotericin B has shown promising therapeutic effects as an inhalation treatment for pulmonary fungal infections, especially those associated with the
Juan Wang +3 more
doaj +2 more sources
Lung surfactant in subacute pulmonary disease [PDF]
Respiratory Research, 2002 Pulmonary surfactant is a surface active material composed of both lipids and proteins that is produced by alveolar type II pneumocytes. Abnormalities of surfactant in the immature lung or in the acutely inflamed mature lung are well described.
Spragg Roger G, Devendra Gehan
doaj +2 more sources
Bio-inspired pulmonary surfactant-modified nanogels : a promising siRNA delivery system [PDF]
, 2015 Inhalation therapy with small interfering RNA (siRNA) is a promising approach in the treatment of pulmonary disorders. However, clinical translation is severely limited by the lack of suitable delivery platforms.
Braeckmans, Kevin +5 more
core +17 more sources
Insights Gained Into the Treatment of COVID19 by Pulmonary Surfactant and Its Components
Frontiers in Immunology, 2022 Pulmonary surfactant constitutes an important barrier that pathogens must cross to gain access to the rest of the organism via the respiratory surface.
Dan Li +6 more
doaj +1 more source